gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2025-35-3-94-103gastro-j-1494Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL ARTICLESЛекарственное повреждение печени и вероятность гепатоцеллюлярного рака на фоне химиотерапии колоректального рака (метаанализ)Drug-Induced Liver Injury and the Likelihood of Hepatocellular Carcinoma During Chemotherapy for Colorectal Cancer (Meta-Analysis)https://orcid.org/0000-0003-2330-4229ГармановаТ. Н.GarmanovaT. N.

Гарманова Татьяна Николаевна — кандидат медицинских наук, доцент кафедры хирургических болезней, ведущий научный сотрудник отдела хирургии и онкологии, Медицинский научно-образовательный институт

 

119991, г. Москва, Ленинские горы, 1

 

Tatyana N. Garmanova — Cand. Sci. (Med.), Associate Professor of the Department of Surgical Diseases, Leading Researcher of the Department of Surgery and Oncology, Medical Research and Educational Institute

119991, Moscow, Leninskie gory, 1 

tatianagarmanova@gmail.comhttps://orcid.org/0000-0003-2711-2400МаркарьянД. Р.MarkaryanD. R.

Маркарьян Даниил Рафаэлевич — кандидат медицинских наук, старший научный сотрудник отдела хирургии и онкологии, заведующий отделением абдоминальной и торакальной онкологии, Медицинский научно-образовательный институт

119991, г. Москва, Ленинские горы, 1

Daniil R. Markaryan — Cand. Sci. (Med.), Senior Researcher at the Department of Surgery and Oncology, Head of the Department of Abdominal and Thoracic Oncology, Medical Research and Educational Institute

119991, Moscow, Leninskie gory, 1 

dmarkaryan@gmail.comhttps://orcid.org/0000-0001-6322-7016КазаченкоЕ. А.KazachenkoE. A.

Казаченко Екатерина Александровна — аспирант кафедры хирургических болезней, Медицинский научно-образовательный институт

119991, г. Москва, Ленинские горы, 1

Ekaterina A. Kazachenko — Postgraduate of the Department of Surgical Diseases, Medical Research and Educational Institute

119991, Moscow, Leninskie gory, 1 

ekaterina.k.97@mail.ruhttps://orcid.org/0000-0002-3436-7201ТишкинГ. В.TishkinG. V.

Тишкин Герман Васильевич — ординатор кафедры хирургических болезней Медицинский научно-образовательный институт

119991, г. Москва, Ленинские горы, 1

German V. Tishkin — Resident of the Department of Surgical Diseases, Medical Research and Educational Institute

119991, Moscow, Leninskie gory, 1 

lem19051917@gmail.comhttps://orcid.org/0000-0002-7999-8955ИщенкоР. В.IshchenkoR. V.

Ищенко Роман Викторович — доктор медицинских наук, профессор кафедры хирургических болезней, Медицинский научно-образовательный институт

 

119991, г. Москва, Ленинские горы, 1

 

Roman V. Ishchenko — Dr. Sci. (Med.), Professor of the Department of Surgical Diseases, Medical Research and Educational Institute

119991, Moscow, Leninskie gory, 1

ishenkorv@rambler.ruФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова»РоссияM.V. Lomonosov Moscow State UniversityRussian Federation20251308202535394103Copyright © Гарманова Т.Н., Маркарьян Д.Р., Казаченко Е.А., Тишкин Г.В., Ищенко Р.В., 20252025Гарманова Т.Н., Маркарьян Д.Р., Казаченко Е.А., Тишкин Г.В., Ищенко Р.В.Garmanova T.N., Markaryan D.R., Kazachenko E.A., Tishkin G.V., Ishchenko R.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1494

Опухолевые заболевания — одна из ведущих причин смерти в мире. Неоадъювантная и адъювантная химиотерапии потенциально могут вести к лекарственному поражению печени и карциноме. По данным обзора литературы и метаанализа, средняя взвешенная частота лекарственных повреждений печени для всех препаратов среди пациентов, получающих неоадъювантную химиотерапию по поводу колоректального рака с метастазами в печень, равна 63,2 %. Средняя взвешенная частота тяжелых поражений печени равна 37,2 %. Однако нами не было обнаружено клинических сообщений о формировании карциномы печени вследствие проведения химиотерапии. В настоящее время мы можем сказать, что, несмотря на теоретическую возможность, прием химиотерапии при колоректальном раке не сопровождается развитием гепатоцеллюлярной карциномы.

Tumor diseases are one of the leading causes of death worldwide. Neoadjuvant and adjuvant chemotherapy can potentially lead to drug-induced liver injury and carcinoma. According to the literature review and meta-analysis, the mean weighted incidence of drug-induced liver injuries for all drugs among patients receiving neoadjuvant chemotherapy for colorectal cancer with liver metastases is 63.2 %. The mean weighted incidence of severe liver injury is 37.2 %. However, we have not found clinical reports of liver carcinoma formation due to chemotherapy. At present, we can say that, despite the theoretical possibility, chemotherapy for colorectal cancer is not accompanied by the development of hepatocellular carcinoma.

лекарственные поражения печенихимиотерапияоксалиплатиниринотеканколоректальный ракгепатоцеллюлярная карциномаметаанализdrug-induced liver injurychemotherapyoxaliplatinirinotecancolorectal cancerhepatocellular carcinomameta-analysisReferencesSung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca A Cancer Journal for Clinicians. 2021;71(3):209–49. DOI: 10.3322/caac.21660Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca A Cancer Journal for Clinicians. 2021;71(3):209–49. DOI: 10.3322/caac.21660Björnsson E.S., Stephens C., Atallah E., Robles-Diaz M., Alvarez-Alvarez I., Gerbes A., et al. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. Liver Int. 2023;43(1):115–26. DOI: 10.1111/liv.15378Björnsson E.S., Stephens C., Atallah E., Robles-Diaz M., Alvarez-Alvarez I., Gerbes A., et al. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. Liver Int. 2023;43(1):115–26. DOI: 10.1111/liv.15378Han J., Liu J., Yu Z., Huang R., Zhao L., Xu Y., et al. Risk factors for irinotecan-induced liver injury: A retrospective multicentre cross-sectional study in China. BMJ open. 2023;13(6):e069794. DOI: 10.1136/bmjopen-2022-069794Han J., Liu J., Yu Z., Huang R., Zhao L., Xu Y., et al. Risk factors for irinotecan-induced liver injury: A retrospective multicentre cross-sectional study in China. BMJ open. 2023;13(6):e069794. DOI: 10.1136/bmjopen-2022-069794Zeien J., Qiu W., Triay M., Dhaibar H.A., Cruz-Topete D., Cornett E.M., et al. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care. Biomed Pharmacother. 2022;146:112503. DOI: 10.1016/j.biopha.2021.112503Zeien J., Qiu W., Triay M., Dhaibar H.A., Cruz-Topete D., Cornett E.M., et al. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care. Biomed Pharmacother. 2022;146:112503. DOI: 10.1016/j.biopha.2021.112503Arjmand A., Tsipouras M.G., Tzallas A.T., Forlano R., Manousou P., Giannakeas N. Quantification of liver fibrosis — A comparative study. Applied Sciences. 2020;10(2):447. DOI: 10.3390/app10020447Arjmand A., Tsipouras M.G., Tzallas A.T., Forlano R., Manousou P., Giannakeas N. Quantification of liver fibrosis — A comparative study. Applied Sciences. 2020;10(2):447. DOI: 10.3390/app10020447Narita M., Oussoultzoglou E., Chenard M.P., Fuchshuber P., Rather M., Rosso E., et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol. 2012;19(7):2230–7. DOI: 10.1245/s10434-011-2112-6Narita M., Oussoultzoglou E., Chenard M.P., Fuchshuber P., Rather M., Rosso E., et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol. 2012;19(7):2230–7. DOI: 10.1245/s10434-011-2112-6Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Rev Panam Salud Publica. 2022;46:e112. DOI: 10.26633/rpsp.2022.112Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Rev Panam Salud Publica. 2022;46:e112. DOI: 10.26633/rpsp.2022.112Saracoglu I., Akin E., Aydin Dincer G.B. Efficacy of adding pain neuroscience education to a multimodal treatment in fibromyalgia: A systematic review and meta-analysis. Int J Rheum Dis. 2022;25(4):394–404. DOI: 10.1111/1756-185X.14293Saracoglu I., Akin E., Aydin Dincer G.B. Efficacy of adding pain neuroscience education to a multimodal treatment in fibromyalgia: A systematic review and meta-analysis. Int J Rheum Dis. 2022;25(4):394–404. DOI: 10.1111/1756-185X.14293Zhang Y., Huang L., Wang D., Ren P., Hong Q., Kang D. The ROBINS-I and the NOS had similar reliability but differed in applicability: A random sampling observational studies of systematic reviews/meta-analysis. J Evid Based Med. 2021;14(2):112–22. DOI: 10.1111/jebm.12427Zhang Y., Huang L., Wang D., Ren P., Hong Q., Kang D. The ROBINS-I and the NOS had similar reliability but differed in applicability: A random sampling observational studies of systematic reviews/meta-analysis. J Evid Based Med. 2021;14(2):112–22. DOI: 10.1111/jebm.12427Luchini C., Veronese N., Nottegar A., Shin J.I., Gentile G., Granziol U., et al. Assessing the quality of studies in meta-research: Review/guidelines on the most important quality assessment tools. Pharm Stat. 2021;20(1):185–95. DOI: 10.1002/pst.2068Luchini C., Veronese N., Nottegar A., Shin J.I., Gentile G., Granziol U., et al. Assessing the quality of studies in meta-research: Review/guidelines on the most important quality assessment tools. Pharm Stat. 2021;20(1):185–95. DOI: 10.1002/pst.2068Soubrane O., Brouquet A., Zalinski S., Terris B., Brézault C., Mallet V., et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: Correlation with post-hepatectomy outcome. Ann Surg. 2010;251(3):454–60. DOI: 10.1097/SLA.0b013e3181c79403Soubrane O., Brouquet A., Zalinski S., Terris B., Brézault C., Mallet V., et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: Correlation with post-hepatectomy outcome. Ann Surg. 2010;251(3):454–60. DOI: 10.1097/SLA.0b013e3181c79403Mehta N.N., Ravikumar R., Coldham C.A., Buckels J.A.C., Hubscher S.G., Bramhall S.R., et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34(7):782–6. DOI: 10.1016/j.ejso.2007.09.007Mehta N.N., Ravikumar R., Coldham C.A., Buckels J.A.C., Hubscher S.G., Bramhall S.R., et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34(7):782–6. DOI: 10.1016/j.ejso.2007.09.007Rubbia-Brandt L., Lauwers G.Y., Wang H., Majno P.E., Tanabe K., X Zhu A. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56(4):430–9. DOI: 10.1111/j.1365-2559.2010.03511.xRubbia-Brandt L., Lauwers G.Y., Wang H., Majno P.E., Tanabe K., X Zhu A. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56(4):430–9. DOI: 10.1111/j.1365-2559.2010.03511.xNordlinger B., Benoist S., Penna C. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;244(5):835.Nordlinger B., Benoist S., Penna C. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;244(5):835.Narita M., Oussoultzoglou E., Jaeck D. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18(Suppl. 3):S310. DOI: 10.1245/s10434-011-1936-4Narita M., Oussoultzoglou E., Jaeck D. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18(Suppl. 3):S310. DOI: 10.1245/s10434-011-1936-4Viganò L., Capussotti L., De Rosa G., De Saussure W.O., Mentha G., Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258(5):731–42. DOI: 10.1097/SLA.0b013e-3182a6183eViganò L., Capussotti L., De Rosa G., De Saussure W.O., Mentha G., Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258(5):731–42. DOI: 10.1097/SLA.0b013e-3182a6183eMiura K., Nakano H., Sakurai J., Kobayashi S., Koizumi S., Arai T., et al. Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol. 2011;16(3):257–63. DOI: 10.1007/s10147-010-0176-0Miura K., Nakano H., Sakurai J., Kobayashi S., Koizumi S., Arai T., et al. Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol. 2011;16(3):257–63. DOI: 10.1007/s10147-010-0176-0Karoui M., Penna C., Amin-Hashem M., Mitry E., Benoist S., Franc B., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7. DOI: 10.1097/01.sla.0000193603.26265.c3Karoui M., Penna C., Amin-Hashem M., Mitry E., Benoist S., Franc B., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7. DOI: 10.1097/01.sla.0000193603.26265.c3Tamandl D., Klinger M., Eipeldauer S., Herberger B., Kaczirek K., Gruenberger B., et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18(2):421–30. DOI: 10.1245/s10434-010-1317-4Tamandl D., Klinger M., Eipeldauer S., Herberger B., Kaczirek K., Gruenberger B., et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18(2):421–30. DOI: 10.1245/s10434-010-1317-4Галимова С.Ф. Лекарственные поражения печени (Часть 1-я). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012;22(3):38–48.Galimova S.F. Drug-induced liver injuries (part I). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(3):38–48. (In Russ.).Real M., Barnhill M.S., Higley C., Rosenberg J., Lewis J.H. Drug-induced liver injury: Highlights of the recent literature. Drug Safety. 2019;42(3):365–87. DOI: 10.1007/s40264-018-0743-2Real M., Barnhill M.S., Higley C., Rosenberg J., Lewis J.H. Drug-induced liver injury: Highlights of the recent literature. Drug Safety. 2019;42(3):365–87. DOI: 10.1007/s40264-018-0743-2Sun Y.K., Zhang Y.F., Xie L., Rong F., Zhu X.Y., Xie J., et al. Progress in the treatment of drug-induced liver injury with natural products. Pharmacol Res. 2022;183:106361. DOI: 10.1016/j.phrs.2022.106361Sun Y.K., Zhang Y.F., Xie L., Rong F., Zhu X.Y., Xie J., et al. Progress in the treatment of drug-induced liver injury with natural products. Pharmacol Res. 2022;183:106361. DOI: 10.1016/j.phrs.2022.106361Garcia-Cortes M., Robles-Diaz M., Stephens C., Ortega-Alonso A., Lucena M.I., Andrade R.J. Drug induced liver injury: An update. Arch Toxicol. 2020;94(10):3381–407. DOI: 10.1007/s00204-020-02885-1Garcia-Cortes M., Robles-Diaz M., Stephens C., OrtegaAlonso A., Lucena M.I., Andrade R.J. Drug induced liver injury: An update. Arch Toxicol. 2020;94(10):3381–407. DOI: 10.1007/s00204-020-02885-1Li X., Tang J., Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 2022;42(9):1999–2014. DOI: 10.1111/liv.15262Li X., Tang J., Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 2022;42(9):1999–2014. DOI: 10.1111/liv.15262Björnsson H.K., Björnsson E.S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022;97:26–31. DOI: 10.1016/j.ejim.2021.10.035Björnsson H.K., Björnsson E.S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022;97:26–31. DOI: 10.1016/j.ejim.2021.10.035Andrade R.J., Chalasani N., Björnsson E.S., Suzuki A., Kullak-Ublick G.A., Watkins P.B., et al. Druginduced liver injury. Nat Rev Dis Primers. 2019;5(1):58. DOI: 10.1038/s41572-019-0105-0Andrade R.J., Chalasani N., Björnsson E.S., Suzuki A., Kullak-Ublick G.A., Watkins P.B., et al. Druginduced liver injury. Nat Rev Dis Primers. 2019;5(1):58. DOI: 10.1038/s41572-019-0105-0Strobach D., Benesic A. Drug-induced liver injury. Krankenhauspharmazie. 2023;44(1):3–9.Strobach D., Benesic A. Drug-induced liver injury. Krankenhauspharmazie. 2023;44(1):3–9.Ragab M., Schlichting H., Hicken M., Mester P., Hirose M., Almeida L.N., et al. Azathioprine promotes intestinal epithelial cell differentiation into Paneth cells and alleviates ileal Crohn’s disease severity. Sci Rep. 2024;14(1):12879. DOI: 10.1038/s41598-024-63730-4Ragab M., Schlichting H., Hicken M., Mester P., Hirose M., Almeida L.N., et al. Azathioprine promotes intestinal epithelial cell differentiation into Paneth cells and alleviates ileal Crohn’s disease severity. Sci Rep. 2024;14(1):12879. DOI: 10.1038/s41598-024-63730-4Shojaie L., Iorga A., Dara L. Cell death in liver diseases: A review. Int J Mol Sci. 2020;21(24):9682. DOI: 10.3390/ijms21249682Shojaie L., Iorga A., Dara L. Cell death in liver diseases: A review. Int J Mol Sci. 2020;21(24):9682. DOI: 10.3390/ijms21249682Weber S., Gerbes A.L. Challenges and future of drug-induced liver injury research — Laboratory tests. Int J Mol Sci. 2022;23(11):6049. DOI: 10.3390/ijms23116049Weber S., Gerbes A.L. Challenges and future of drug-induced liver injury research — Laboratory tests. Int J Mol Sci. 2022;23(11):6049. DOI: 10.3390/ijms23116049Devarbhavi H., Aithal G., Treeprasertsuk S., Takikawa H., Mao Y., Shasthry S.M.; Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2020;15(2):258–82. DOI: 10.1007/s12072-021-10144-3Devarbhavi H., Aithal G., Treeprasertsuk S., Takikawa H., Mao Y., Shasthry S.M.; Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2020;15(2):258–82. DOI: 10.1007/s12072-021-10144-3Gijbels E., Vilas-Boas V., Deferm N., Devisscher L., Jaeschke H., Annaert P., et al. Mechanisms and in vitro models of drug-induced cholestasis. Arch Toxicol. 2019;93(5):1169–86. DOI: 10.1007/s00204-019-02437-2Gijbels E., Vilas-Boas V., Deferm N., Devisscher L., Jaeschke H., Annaert P., et al. Mechanisms and in vitro models of drug-induced cholestasis. Arch Toxicol. 2019;93(5):1169–86. DOI: 10.1007/s00204-019-02437-2Hwang D.B., Seo Y., Lee E., Won D.H., Kim C., Kang M.H., et al. Diagnostic potential of serum miR-532-3p as a circulating biomarker for experimental intrinsic drug-induced liver injury by acetaminophen and cisplatin in rats. Food Chem Toxicol. 2023;178:113890. DOI: 10.1016/j.fct.2023.113890Hwang D.B., Seo Y., Lee E., Won D.H., Kim C., Kang M.H., et al. Diagnostic potential of serum miR-532-3p as a circulating biomarker for experimental intrinsic drug-induced liver injury by acetaminophen and cisplatin in rats. Food Chem Toxicol. 2023;178:113890. DOI: 10.1016/j.fct.2023.113890Chen R., Li W., Li R., Ai S., Zhu H., Lin W. Cysteine-activated fluorescence/photoacoustic integrated probe for non-invasive diagnosis of drug-induced liver injury. Chinese Chemical Letters. 2023;34(5):107845. DOI: 10.1016/j.cclet.2022.107845Chen R., Li W., Li R., Ai S., Zhu H., Lin W. Cysteine-activated fluorescence/photoacoustic integrated probe for non-invasive diagnosis of drug-induced liver injury. Chinese Chemical Letters. 2023;34(5):107845. DOI: 10.1016/j.cclet.2022.107845Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62(6):481–92. DOI: 10.1136/jcp.2008.058248Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62(6):481–92. DOI: 10.1136/jcp.2008.058248Ивашкин В.Т., Райхельсон К.Л., Пальгова Л.К., Маевская М.В., Герасимова О.А., Кондрашина Э.А. и др. Лекарственные поражения печени у онкологических пациентов. Онкогематология. 2020;15(3):80–94. DOI: 10.17650/1818-8346-2020-15-3-80-94Ivashkin V.T., Raikhelson K.L., Palgova L.K., Maevskaya M.V., Gerasimova O.A., Kondrashina E.A., et al. Drug-induced liver injury in cancer patients. Oncohematology. 2020;15(3):80–94. (In Russ.). DOI: 10.17650/1818-8346-2020-15-3-80-94Yang X.Q., Ye J., Li X., Li Q., Song Y. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol. 2019;25(28):3753–63. DOI: 10.3748/wjg.v25.i28.3753Yang X.Q., Ye J., Li X., Li Q., Song Y. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol. 2019;25(28):3753–63. DOI: 10.3748/wjg.v25.i28.3753Corbacioglu S., Jabbour E.J., Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25(7):1271–80. DOI: 10.1016/j.bbmt.2019.02.018Corbacioglu S., Jabbour E.J., Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25(7):1271–80. DOI: 10.1016/j.bbmt.2019.02.018Weiss B.M., Sawinski D. Sinusoidal obstruction syndrome. Onco-Nephrology E-Book. 2019;40(4):99–106.e4.Weiss B.M., Sawinski D. Sinusoidal obstruction syndrome. Onco-Nephrology E-Book. 2019;40(4):99–106.e4.Nakano H., Oussoultzoglou E., Rosso E., Casnedi S., Chenard-Neu M.P., Dufour P., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24. DOI: 10.1097/SLA.0b013e31815774deNakano H., Oussoultzoglou E., Rosso E., Casnedi S., Chenard-Neu M.P., Dufour P., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24. DOI: 10.1097/SLA.0b013e31815774deZhu C., Ren X., Liu D., Zhang C. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology. 2021;460:152882. DOI: 10.1016/j.tox.2021.152882Zhu C., Ren X., Liu D., Zhang C. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology. 2021;460:152882. DOI: 10.1016/j.tox.2021.152882Teng Y.X., Xie S., Guo P.P., Deng Z.J., Zhang Z.Y., Gao W., et al. Hepatocellular carcinoma in non-alcoholic fatty liver disease: Current progresses and challenges. J Clin Transl Hepatol. 2022;10(5):955–64. DOI: 10.14218/JCTH.2021.00586Teng Y.X., Xie S., Guo P.P., Deng Z.J., Zhang Z.Y., Gao W., et al. Hepatocellular carcinoma in non-alcoholic fatty liver disease: Current progresses and challenges. J Clin Transl Hepatol. 2022;10(5):955–64. DOI: 10.14218/JCTH.2021.00586Chidambaranathan-Reghupaty S., Fisher P.B., Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61. DOI: 10.1016/bs.acr.2020.10.001Chidambaranathan-Reghupaty S., Fisher P.B., Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61. DOI: 10.1016/bs.acr.2020.10.001Müller M., Bird T.G., Nault J.C. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol. 2020;72(5):990–1002. DOI: 10.1016/j.jhep.2020.01.019Müller M., Bird T.G., Nault J.C. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol. 2020;72(5):990–1002. DOI: 10.1016/j.jhep.2020.01.019Семендяева М.И., Меркулов И.А., Пастухов А.И., Гайдашева Е.В., Лесняк В.Н., Шутова О.В. Гепатоцеллюлярная карцинома — день сегодняшний. Клиническая практика. 2013;2(14):35–49.Semendyaeva M.I., Merculov I.A., Pastukhov A.I., Gaydascheva E.V., Lesnyak V.N., Schutova O.V. Hepatocellular carcinoma today. Journal of Clinical Practice. 2013;2(14):35–49. (In Russ.).Wang W., Gao W., Zhu Q., Alasbahi A., Seki E., Yang L. TAK1: A molecular link between liver inflammation, fibrosis, steatosis, and carcinogenesis. Front Cell Dev Biol. 2021;9:734749. DOI: 10.3389/fcell.2021.734749Wang W., Gao W., Zhu Q., Alasbahi A., Seki E., Yang L. TAK1: A molecular link between liver inflammation, fibrosis, steatosis, and carcinogenesis. Front Cell Dev Biol. 2021;9:734749. DOI: 10.3389/fcell.2021.734749Dhar D., Baglieri J., Kisseleva T., Brenner D.A. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood). 2020;245(2):96–108. DOI: 10.1177/1535370219898141Dhar D., Baglieri J., Kisseleva T., Brenner D.A. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood). 2020;245(2):96–108. DOI: 10.1177/1535370219898141

The authors declare that there are no conflicts of interest present.